Chelsea Therapeutics, Inc. Reports Data From Study 303 Confirming Safety and Robust Therapeutic Benefit of Long-Term Northera Treatment in Neurogenic Orthostatic Hypotension

CHARLOTTE, N.C., May 18, 2010 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) reported preliminary findings from Study 303, a long-term safety extension study from its Phase III NORTHERA™ (droxidopa) registration program in symptomatic neurogenic orthostatic hypotension (NOH). Top-line results demonstrated that prolonged treatment with Northera provides clinically meaningful and durable symptomatic improvements in patients with NOH and the data validate that the drug is safe and well tolerated throughout the extended dosing period.